Compile Data Set for Download or QSAR
maximum 50k data
Found 159 Enz. Inhib. hit(s) with all data for entry = 3468
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401319(US10005762, Example 3)
Affinity DataIC50:  0.580nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401367(US10005762, Example 47)
Affinity DataIC50:  0.650nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401355(US10005762, Example 35)
Affinity DataIC50:  0.940nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401322(US10005762, Example 4(3))
Affinity DataIC50:  1.20nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401350(US10005762, Example 30)
Affinity DataIC50:  1.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401369(US10005762, Example 49)
Affinity DataIC50:  1.5nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401393(US10005762, Example 73)
Affinity DataIC50:  1.5nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401360(US10005762, Example 40)
Affinity DataIC50:  1.60nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401355(US10005762, Example 35)
Affinity DataIC50:  1.60nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401320(US10005762, Example 4(1))
Affinity DataIC50:  1.70nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401317(US10005762, Example 1)
Affinity DataIC50:  1.70nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401368(US10005762, Example 48)
Affinity DataIC50:  1.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401356(US10005762, Example 36)
Affinity DataIC50:  1.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401324(US10005762, Example 6(1) | US10005762, Example 6(2...)
Affinity DataIC50:  1.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401389(US10005762, Example 69)
Affinity DataIC50:  2.10nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401393(US10005762, Example 73)
Affinity DataIC50:  2.20nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401395(US10005762, Example 75)
Affinity DataIC50:  2.30nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401320(US10005762, Example 4(1))
Affinity DataIC50:  2.30nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401354(US10005762, Example 34)
Affinity DataIC50:  2.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401319(US10005762, Example 3)
Affinity DataIC50:  2.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401364(US10005762, Example 44)
Affinity DataIC50:  2.5nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401322(US10005762, Example 4(3))
Affinity DataIC50:  2.60nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401394(US10005762, Example 74)
Affinity DataIC50:  2.60nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401370(US10005762, Example 50)
Affinity DataIC50:  2.70nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401321(US10005762, Example 4(2))
Affinity DataIC50:  2.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401350(US10005762, Example 30)
Affinity DataIC50:  3.10nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401395(US10005762, Example 75)
Affinity DataIC50:  3.10nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401392(US10005762, Example 72)
Affinity DataIC50:  3.20nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401394(US10005762, Example 74)
Affinity DataIC50:  3.20nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401317(US10005762, Example 1)
Affinity DataIC50:  3.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401351(US10005762, Example 31)
Affinity DataIC50:  3.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401367(US10005762, Example 47)
Affinity DataIC50:  3.5nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401369(US10005762, Example 49)
Affinity DataIC50:  3.60nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401388(US10005762, Example 68)
Affinity DataIC50:  3.70nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401347(US10005762, Example 27)
Affinity DataIC50:  3.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401365(US10005762, Example 45)
Affinity DataIC50:  3.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401391(US10005762, Example 71)
Affinity DataIC50:  3.90nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401371(US10005762, Example 51)
Affinity DataIC50:  4nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401375(US10005762, Example 55)
Affinity DataIC50:  4.30nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401351(US10005762, Example 31)
Affinity DataIC50:  4.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401361(US10005762, Example 41)
Affinity DataIC50:  4.40nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401361(US10005762, Example 41)
Affinity DataIC50:  4.5nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401392(US10005762, Example 72)
Affinity DataIC50:  4.60nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401372(US10005762, Example 52)
Affinity DataIC50:  4.90nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401358(US10005762, Example 38)
Affinity DataIC50:  4.90nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401323(US10005762, Example 5)
Affinity DataIC50:  5.10nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401375(US10005762, Example 55)
Affinity DataIC50:  5.20nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401324(US10005762, Example 6(1) | US10005762, Example 6(2...)
Affinity DataIC50:  5.20nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM401323(US10005762, Example 5)
Affinity DataIC50:  5.30nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucyl-cystinyl aminopeptidase(Rattus norvegicus)
Astellas Pharma

US Patent
LigandPNGBDBM401373(US10005762, Example 53)
Affinity DataIC50:  5.80nMAssay Description:The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 159 total ) | Next | Last >>
Jump to: